Neutralizing prolactin receptor antibodies and their therapeutic use

The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the p...

Full description

Saved in:
Bibliographic Details
Main Authors OTTO, CHRISTIANE, WILMEN, ANDREAS, WOLF, SIEGMUND, EICKER, ANDREA, TRAUTWEIN, MARK, BRUDER, SANDRA, FREIBERG, CHRISTOPH, HARRENGA, AXEL, GREVEN, SIMONE
Format Patent
LanguageChinese
English
Published 16.09.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
Bibliography:Application Number: TW201099143332